Epithelial to mesenchymal transition in the metastatic progression of gastroenteropancreatic neuroendocrine tumours by Mok, Stephanie
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-7-2015 12:00 AM 
Epithelial to mesenchymal transition in the metastatic 
progression of gastroenteropancreatic neuroendocrine tumours 
Stephanie Mok 
The University of Western Ontario 
Supervisor 
Dr. Christopher J. Howlett 
The University of Western Ontario Joint Supervisor 
Dr. Douglas Quan 
The University of Western Ontario 
Graduate Program in Pathology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Stephanie Mok 2015 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Pathology Commons 
Recommended Citation 
Mok, Stephanie, "Epithelial to mesenchymal transition in the metastatic progression of 
gastroenteropancreatic neuroendocrine tumours" (2015). Electronic Thesis and Dissertation Repository. 
3021. 
https://ir.lib.uwo.ca/etd/3021 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
EPITHELIAL TO MESENCHYMAL TRANSITION IN THE METASTATIC 
PROGRESSION OF GASTROENTEROPANCREATIC NEUROENDOCRINE 
TUMOURS 
(Thesis format: Monograph) 
 
 
 
by 
 
 
 
Stephanie Yee-Ching Mok  
 
 
 
 
Graduate Program in Pathology and Laboratory Medicine 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Stephanie Mok 2015 
 
 ii 
 
Abstract 
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare type of malignant 
epithelial cancer arising from the diffuse neuroendocrine system.  In this study, we have 
performed gene expression profiling along with immunohistochemistry (IHC) to highlight 
key molecular pathways underlying the pathogenesis of GEP-NETs.  We used formalin-fixed 
paraffin-embedded archived tissue samples of NETs arising from small intestine (SI-NETs), 
pancreas (P-NETs), and distal colon/rectal region (R-NETs) to extract RNA for real-time 
PCR-based gene profiling, and to construct tissue microarrays (TMAs) for high-throughput 
immunohistochemistry.  Our results show evidence of epithelial to mesenchymal transition 
(EMT) at the mRNA and protein levels.  From the genes highlighted by our gene expression 
studies, TGF-β/BMP signalling could be a key mediator towards this EMT event.  Therefore, 
we investigated whether TGF-β signalling is active in GEP-NETs and determined whether its 
activation is linked to an EMT phenotype. 
 
Keywords 
Gastroenteropancreatic neuroendocrine tumours, epithelial to mesenchymal transition, gene 
expression, tissue microarray, immunohistochemistry, transforming growth factor beta 
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Chapter 1  
1 Introduction 
1.1 Diffuse Neuroendocrine System 
The diffuse neuroendocrine system (DNS) refers to a group of cells characterized by the 
expression of neuropeptides, chromogranins, and neuropeptide processing enzymes.  
These cells are widely distributed throughout the body, dispersed throughout different 
tissues in a seeded manner giving it the ‘diffuse’ aspect.  Under electron microscopic 
examination, dense core secretory granules can be seen in the cytoplasm of 
neuroendocrine cells. A “salt and pepper” appearance under light microscopy is also 
commonly used to describe their nuclei which contain granular chromatin.  However, the 
key aspects of a neuroendocrine cell can be further defined by several traits.  They have 
the capacity to produce neurotransmitter, neuromodulator, or neuropeptide hormones, and 
their product is contained within vesicles which are released, upon neural stimulation, via 
exocytosis.  Their mode of transmission is thus endocrine.  Although they stain for some 
neuromarkers such as synaptophysin, they differ from neurons by their lack of axons and 
nerve terminals.   
The DNS provides coordinated actions for the nervous system to influence the functions 
of internal organs, especially along the gastrointestinal tract where a number of different 
neuroendocrine cells and their specific hormone products act in concert to facilitate 
digestion (Table 1.1).  The embryonic origins of the diffuse neuroendocrine cells are 
controversial.  Early postulates believed that neuroendocrine cells, despite their 
distribution throughout the body, arose from a common embryological origin in the 
neuroectoderm or neural crest given their coordinated actions with the nervous system.1, 2  
However, a number of cells having neuroendocrine features have been shown to originate 
from other regions.3 Neuroendocrine cells in the gastrointestinal system are now thought 
to have the same endodermal origins as their other epithelial counterparts.4, 5   
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Table 1.1: Neuroendocrine cells found along the gastrointestinal system 
Neuroendocrine cell Hormone Product Effect 
Enterochromaffin Serotonin Regulates intestinal movement 
Delta Somatostatin 
Reduces acid production of 
parietal cells 
Epsilon (Gr) Ghrelin Inducing appetite 
L Glucagon-like peptide 
Stimulates insulin release; 
decrease glucagon release 
N Neurotensin Smooth muscle contraction 
VIP 
Vasoactive intestinal 
peptide 
Regulates secretion and 
absorption to increase motility 
Alpha (A) Glucagon Elevates blood glucose level 
Beta Insulin Lowers blood glucose level 
I Cholecystokinin (CCK) Bile secretion 
Gamma (PP) Pancreatic polypeptide Inhibits secretions by CCK 
G Gastrin Stimulates gastric acid secretion 
S Secretin 
Regulates exocrine pancreatic 
secretions 
K Gastric inhibitory peptide 
Incretin; promotes triglyceride 
storage 
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1.2 Gastroenteropancreatic Neuroendocrine Tumours 
Tumours can arise from cells of the diffuse neuroendocrine system and may appear 
anywhere in the body.  The last few decades has seen an increase in incidence of 
neuroendocrine tumours (NETs) from 1.09 per 100,000 in 1973 to 5.25 per 100,000 in 
2004,6 with the majority of these tumours appearing along the gastrointestinal tract 
(60.52%) and the bronchopulmonary system (27.4%).7  
Scattered in the mucosa of the entire digestive tract and pancreatic ducts, gastrointestinal 
neuroendocrine cells are responsible for producing and secreting over 20 different 
peptide hormones including gastrin, cholecystokinin (CCK), serotonin and somatostatin.  
Lesions that appear along the gastrointestinal tract, including the pancreas, are 
collectively referred to as gastroenteropancreatic neuroendocrine tumours (GEP-NETs).  
Within this classification, the most common sites for GEP-NETs are the small intestine 
(also colloquially referred to as carcinoid tumours), rectum, colon, followed by the 
pancreas.7   
 
1.2.1 Signs and Symptoms  
GEP-NETs are typically small (less than 1 cm), slow-growing tumours that tend to 
remain clinically silent for many years.  Discovery of these lesions are often incidental, 
and sometimes a distant metastasis is discovered before the primary lesion is located.  
The symptoms caused by GEP-NETs tend to be non-specific and are often overlooked or 
misdiagnosed.  Common signs and symptoms pertaining to GEP-NETs include diarrhoea, 
flushing, abdominal pain, gastrointestinal bleeding, bronchoconstriction, and cardiac 
palpitations.8  The combination of these symptoms due to a GEP-NET is known as 
carcinoid syndrome.  This syndrome does not manifest in every case of GEP-NET, but it 
often represents a later stage in the disease when it appears.  For this constellation of 
symptoms to appear, a number of events typically occur beforehand.  First, the GEP-NET 
must be a functional tumour capable of producing an active and secreted hormone 
product.  Second, the hormone product has to be able to pass through the liver without 
being metabolized to access the systemic circulation and exert its effect.  The second 
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condition is typically met after a metastatic event has occurred to the liver such that the 
hormone product bypasses hepatic circulation.  This is why the appearance of the 
carcinoid syndrome is a late event in the disease progression.  
 
1.2.2 Classification, Grading, and Staging 
GEP-NETs are commonly classified as a group of heterogeneous tumours.  Part of this 
heterogeneity comes from the difficulty in predicting its clinical behaviour when 
identified.  The current grading systems rely heavily on Ki-67 proliferation index to make 
these predictions (Table 1.2).  Variations in Ki-67 grade cut-offs and interpersonal 
variation in interpreting Ki-67 results may account for some problems in accurately 
grading the disease, however it reflects a greater need for a more precise grading 
scheme.9, 10  The classification of GEP-NETs relies on three main parameters: degree of 
differentiation, whether the tumour is functional (hormone-secreting) or non-functional, 
and its proliferation index measured by Ki-67 or mitotic figure counts.11  There are 
several parallel grading and staging systems that use these parameters as a foundation for 
classifying GEP-NETs: the 2010 World Health Organization (WHO) classification 
system, the European Neuroendocrine Tumour Society guidelines, and the American 
Joint Committee on Cancer/Union for international Cancer Control guidelines.  
Unfortunately, these systems are largely viewed as an imprecise way of assigning grade 
and stage to the NETs because the biological behaviour of the tumours are quite variable 
within a given grade and do little to predict malignant behaviour.  Furthermore, the 
differences between the staging systems can create confusion.12  Thus, there is need for a 
better understanding of the molecular mechanisms involved in the pathogenesis of the 
disease and a more unified classification system.13, 14  This limitation may explain why 
the overall 5-year survival rate of NETs has remained unchanged at 60% over the last 
few decades.15  
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Table 1.2: 2010 WHO Grading for GEP-NETs 
Differentiation Grade GEP-NETs 
Well Differentiated Low (G1) 
<2 mitoses / 10 hpf AND <3% 
Ki67 index 
 
Intermediate (G2) 
2-20 mitoses / 10 hpf OR 3%-
20% Ki67 index 
Poorly Differentiated High (G3) 
>20 mitoses / 10 hpf OR >20% 
Ki67 index 
 
1.2.3 Histology of GEP-NETs – Characteristics and stains 
GEP-NETs can extend from the mucosa through the serosa depending on its size. 
Confirmation of a GEP-NET is done by immunohistochemical reactivity to common 
neuroendocrine markers including chromogranin, synaptophysin, CD56, and neuron 
specific enolase (NSE).  Morphologically, the growth pattern of GEP-NETs can be 
described as gyriform, nesting, solid/insular, trabecular and/or acinar, but they have no 
influence on its classification (Figure 1.1).  Cytologically, they have round nuclei with 
speckled chromatin giving it a “salt and pepper” appearance along with small nucleoli 
that may or may not be prominent depending on the site of origin (Figure 1.2).  At low 
power magnification, the cells look small with abundant cytoplasm that, at higher 
magnification, shows granularity.  The cells of a well-differentiated GEP-NET look 
similar between tumours from different anatomical sites.  Sometimes the cells of GEP-
NETs are described as monotonous given how similar they look to one another.  
Furthermore, the well-differentiated appearance of most of these tumours belies its 
metastatic potential.  Despite these similarities, GEP-NETs from different anatomical 
sites demonstrate some histological differences, and certain neuroendocrine markers are 
more effective at detecting neuroendocrine phenotypes in different locations.16  For 
example, rectal NETs can stain for more specific polypeptides such as somatostatin, 
glucagon, substance P, and peptide YY as well. 
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Figure 1.1. Representative images of GEP-NET morphologic growth patterns. 
Tumours pictured here show (A) acinar, (B) gyriform, (C) nested, (D) solid, and (E) 
trabecular growth patterns. 
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Figure 1.2. High powered image showing "salt and pepper" chromatin pattern, 
characteristic of neuroendocrine tumours. 
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1.2.4 Treatments  
Treatment for these tumours is often done in consultation with a multidisciplinary team 
of physicians from different specialities.  Complete surgical excision is often the best and 
the only curative option for individuals diagnosed with GEP-NETs.  However, this may 
not always be feasible given the patient profile, location of the lesion or tumour burden.  
In this case, symptomatic management and control of tumour growth become the primary 
treatment goals.  Debulking surgery may be part of this treatment regime to reduce a 
patient’s tumour burden and its mass effect.  Many patients diagnosed with a GEP-NET 
will begin with Octreotide therapy, a somatostatin analogue that can inhibit or reduce the 
effects of hormones that may be excessively produced by the tumour.  Cytoreductive 
therapy including the use of certain chemotherapeutic agents may also be part of treating 
the GEP-NET, although with varying efficacy possibly due to the low proliferation rate 
of these tumours.  Novel and investigational therapeutic agents aim to control tumour 
growth such as the mammalian target of rapamycin (mTOR) inhibitor, Everolimus, and 
the anti-angiogenic agent Sunitinib.17, 18 
Unfortunately, with time, many of these tumours will eventually metastasize despite their 
benign appearance.  In fact, lesions of any size have the potential to metastasize and 
patients not uncommonly present with a metastasis at initial diagnosis.19 
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1.3 The PI3K-AKT/mTOR signalling pathway and GEP-
NETs 
Numerous studies on GEP-NETs have recently demonstrated a key role for the PI3K-
AKT/mTOR pathway in tumourigenesis, particularly in pancreatic neuroendocrine 
tumours (P-NETs).  mTOR signalling is key in regulating protein translation and 
dysregulation along this pathway is thought to allow for uncontrolled, elevated protein 
synthesis driving tumour growth.  In this pathway, the mammalian target of rapamycin 
(mTOR) protein, as either mechanistic target of rapamycin complex 1 or 2 (mTORC1 or 
mTORC2) has serine/threonine kinase activity (Figure 1.3).  It acts to phosphorylate 
transcription factors ribosomal protein S6 kinase beta-1 (S6K1) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1). Phosphorylated S6K1 (p-
S6K1) goes on to enhance the translation of proteins whereas phosphorylated 4EBP1 (p-
4EBP1) relieves inhibition of the eukaryotic transcription factor its non-phosphorylated 
form exerts.  Regulating the mTOR protein are several upstream checkpoints.  
Phosphoinositide 3-kinase (PI3K), which normally resides at the cell membrane, is 
responsible for converting phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3).  PIP3 is then able to promote the 
phosphorylation of protein kinase B (AKT) which goes on to phosphorylate tuberous 
sclerosis complex (TSC) proteins that constitutively repress mTOR.  Phosphatase and 
tensin homolog (PTEN) converts PIP3 back to PIP2 to reduce mTOR activation.  PI3K 
activation is dependent on receptor tyrosine kinases like the vascular endothelial growth 
factor receptor (VEGFR).  
Exomic sequencing of pancreatic neuroendocrine tumours (P-NETs) revealed that 14% of 
tumours had mutations in genes along this pathway.20  Similar proportions of GEP-NET 
patients were found to have alterations in the PI3k-AKT/mTOR pathway in an exome 
sequencing study for neuroendocrine tumours of the small intestine (SI-NETs), which 
also revealed amplification of AKT genes were the most common event.21  Based upon 
finding phosphorylated (activated) mTOR pathway related proteins such as 
phosphorylated mTOR (p-mTOR) in poorly differentiated GEP-NETs, other studies have 
suggested that mTOR inhibitors would be effective in treating advanced disease.22  
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mTOR expression was similarly found in cases with higher proliferative capacity and 
expression with its downstream effector, phosphorylated S6K1 (p-S6K1), was associated 
with poorer prognosis.23  Upstream inhibitors of mTOR, namely TSC2 and PTEN, were 
found to be down-regulated in a significant number of tumours.24  
 
 
 
Figure 1.3. Schematic illustrating PI3K-AKT/mTOR signalling. 
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1.4 Transforming growth factor beta superfamily 
Transforming growth factor beta (TGF) superfamily and its downstream signalling 
pathways have a broad spectrum of effects depending on cell type, environment, and 
magnitude of signalling.  Members of this superfamily including TGFβ, BMP, and 
activins, have been implicated as effectors of epithelial to mesenchymal transition (EMT) 
via suppression of epithelial traits and promotion of mesenchymal ones.25, 26  For 
example, transforming growth factor beta 3 ligand (TGF-3) is essential for proper cleft 
palate fusion, as knockout TGF-β3 mice are born with a cleft palate.27  Furthermore, it 
has a role in extracellular matrix (ECM) production and growth factors that encourage 
cell migration and invasiveness.   
TGF ligands exist in three isoforms (-1, -2, -3).  Although they share >76% of their 
sequence homology28, they seem to play non-redundant roles in embryonic development 
and wound healing, as reviewed by Finnison et al. (2013).29  TGF-1 is the predominant 
isoform in adults.  This molecule is synthesized as a pro-protein and exists as a 
homodimer.  When secreted, TGF-1 still contains the latency-associated peptide (LAP), 
which couples with the latent TGF binding protein (LTBP) ultimately forming the larger 
latent complex (LLC).  The LLC attaches to ECM proteins where it remains until the 
active form is released by matrix metalloproteinases (MMPs), plasmin or any number of 
conditions involving pH, temperature, and shear stress.30-33 
The TGF receptors are transmembrane serine/threonine receptor kinases.  There are 
three types of TGF receptors which are often present at the membrane in pairs.  The 
complete TGF receptor signalling complex exists as a tetramer.  Binding of a TGF 
ligand brings the two pairs of receptors together to form the complete signalling complex. 
In the canonical TGF/SMAD signalling axis, the association of the two receptor pairs 
allows the receptor to phosphorylate particular SMAD proteins which can then form a 
protein trimer complex with SMAD4 to translocate into the nucleus and regulate 
transcription.34  Specific TGF superfamily ligands bind to certain receptors to activate a 
specific set of SMAD proteins.  TGF ligand binding and receptor activation results in 
the phosphorylation of SMAD2 and SMAD3 whereas BMP binding to its respective 
12 
 
receptor results in the phosphorylation of SMAD1, SMAD5 and SMAD8 (Figure 1.4).  
Within the nucleus, these SMAD complexes have been shown to upregulate the 
transcription of EMT transcription factors such as ZEB1, ZEB2, SNAIL, and TWIST 
which act to suppress E-cadherin expression.35 
In wound healing, elevated TGF signalling has been shown to promote fibrosis to levels 
that compromise normal tissue function.36  Interestingly, GEP-NETs tend to be 
surrounded by fibrotic tissue.  In fact, certain symptoms, such as abdominal pains, are a 
result of the extensive fibrosis surrounding the primary lesion, rather than the tumour 
itself.  Given that TGF signalling is related to fibrosis, it is possible that this pathway is 
active in GEP-NETs and could contribute to the malignant potential of these tumours.   
 
 
Figure 1.4. Schematic illustrating canonical TGF-β/BMP/SMAD signalling axis in 
initiating EMT. 
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1.5 Epithelial to Mesenchymal Transition 
1.5.1 Epithelial phenotype vs mesenchymal phenotype  
Epithelial cells have an organized cobble stone-like appearance where they maintain 
complete contact with one another through a combination of tight junctions, adherens 
junctions, desmosomes, and gap junctions.  These cells form layers with apical-
basolateral polarization evident through their organization of actin cytoskeleton, presence 
of a basal lamina at the basal side, and cell-cell junctions keeping the cells bound 
laterally.  Epithelial cells are capable of moving within the epithelial layer, and do not 
move away from it under normal conditions.  
In contrast, mesenchymal cells are not as closely attached to one another as epithelial 
cells are.  They interact more closely with the extracellular matrix through focal 
adhesions, and their cytoskeletal structure differs in protein composition and organization 
as well.  These cells are characterized as long, thin, and spindle-shaped in their 
morphology and are not associated with a basal lamina.  Mesenchymal cells are known to 
be more mobile than epithelial cells. 
Epithelial to mesenchymal transition (EMT) describes the process of epithelial cells 
losing their cell-cell interactions and adhesions to gain a more mobile, mesenchymal 
phenotype.  This transition can be noted through changes in protein expression and/or 
subcellular localization, polarity, morphology, and migratory or invasive behaviour.37  
The process begins with an EMT effector that triggers a loss of tight junctions, adherens 
junctions and desmosomes that previously anchor the epithelial cells to each other.  
Following this, cytoskeletal changes occur, including the formation of actin stress fibres 
that help promote cell mobility.  Genes involved in matrix remodelling are also 
transcribed and expressed during the transition, ultimately leading to increased motility, 
invasiveness, and migration through the basement membrane. 
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Figure 1.5. Schematic illustrating the changes involved in epithelial to mesenchymal 
transition. 
 
EMT status can be implicated through fluctuations in epithelial and mesenchymal marker 
expression (Table 1.3).  For example, cells demonstrating a diminished expression of 
epithelial markers like E-cadherin and cytokeratin, with an increase in mesenchymal 
markers like vimentin and α-smooth muscle actin could be interpreted as undergoing 
EMT.  E-cadherin is an especially important epithelial marker because it is involved in 
the formation of adherens junctions (with actin) and desmosomes (with intermediate 
filaments) which make up some of the cell-cell adhesions typically seen in an epithelial 
tissue.38, 39  They associate with β-catenin along the membrane to interact with these 
cytoskeletal components in the cell.  The loss of E-cadherin also results in the release of 
β-catenin into the cytoplasm where it can either be ubiquitinated and degraded, or be 
stabilized by active Wnt signalling to translocate into the nucleus and act as a 
transcription factor.39, 40  
The induction of EMT can also be represented morphologically as changes in the apical-
basal polarity and cytoskeletal rearrangements during the process produces spindle-
shaped cells versus their previous cobble-stone appearance.  This can be visualized 
through the shift from cytokeratin expression to α-smooth muscle actin expression.  The 
elongated striations of the contractile α-smooth muscle actin facilitate mesenchymal cell-
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like migration.  Demonstrating the functional changes associated with EMT through 
migration assays of transformed epithelial cells is another way of demonstrating the 
process. 
Although the phenotypic changes seem dramatic, the EMT process is entirely reversible 
through a complementary process known as mesenchymal to epithelial transition (MET).  
Furthermore, a cell may not need to shed all of its epithelial traits and shift entirely 
towards a mesenchymal phenotype.  Intermediate or hybrid states with cells expressing a 
mixed lineage exist and these states may confer enough traits for the transition cell to 
achieve its goal.  Studies have described a spectrum of EMT intermediates which have 
been characterized based on their invasiveness, adhesion, and motility.41, 42  Thus there is 
an element of phenotypic fluidity in epithelial cells to shift towards a mesenchymal 
phenotype and back.  
Table 1.3: Common epithelial and mesenchymal markers 
Epithelial markers Mesenchymal markers 
E-cadherin 
Cytokeratin 
Zona occludens protein 1  
Claudin 
Occludin 
N-cadherin 
Vimentin 
Alpha smooth muscle actin 
Fibronectin 
Fibroblast specific protein 1 
 
1.5.2 Different types of EMT 
Epithelial to mesenchymal transition has been characterized in three different biological 
contexts, described as the three types of EMT.43  Type 1 occurs during development. 
EMT plays a role in implantation and embryogenesis including the formation of the 
mesendoderm that gives rise to the mesoderm and endoderm, neural crest formation, and 
heart valve formation.  
Type 2 EMT is associated with wound healing and fibrosis.  When injury occurs in 
epithelial tissue, cells from the remaining epithelial layer undergo an EMT to manoeuvre 
past the basement membrane into the interstitial space, become fibroblastic and 
contribute to tissue regeneration. 
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The third type of EMT occurs in the context of cancer referring to an early step in the 
metastatic process whereby cancer cells transiently gain a more mobile, mesenchymal-
like phenotype giving it the ability to migrate past the basement membrane, leave their 
primary site, enter the blood stream and travel to a distant site to form a secondary 
tumour after transition back to an epithelial phenotype by MET.  EMT has been 
demonstrated in many epithelial derived cancers including breast, lung, prostate, and 
ovarian.  
 
1.5.3 Transcription factors in EMT 
Several families of transcription factors are involved in inducing EMT, three of which are 
related to transforming growth factor beta (TGFβ)/bone morphogenetic protein (BMP) 
signalling and include the Snail, zinc finger E-box binding proteins (ZEB), and helix-
loop-helix family factors.  All these transcription factors share a common role in 
repressing E-cadherin while promoting certain mesenchymal characteristics, be it marker 
expression or invasive capabilities.44  
The Snail family is comprised of SNAIL1, SNAIL2 (also known as SLUG), and 
SNAIL3. The Snail proteins differ in the combination of co-repressors they complex 
with, and affinities for different target genes.45, 46  Their expression downstream of TGFβ 
results in cadherin switch (i.e. E-cadherin to N-cadherin) and allows for EMT. The Snail 
promoter has been shown to be directly activated by TGFβ signalling via SMAD2, 3 and 
4.47-49  BMP signalling has been shown to directly activate SLUG promoters as well.50  
The role of Snail proteins in the EMT process was hinted at by the failure of Snail-
deficient mouse embryos to form a proper mesodermal layer with sustained E-cadherin 
expression.51  Similar mesodermal defects as well as malformations of the neural crest 
were seen in SLUG deficient chick embryos.52  
ZEB transcription factors exist as either ZEB1 or ZEB2, also known as SMAD-
interacting protein 1 (SIP1), in humans.  ZEB proteins have been shown to interact with 
SMAD3 to regulate TGFβ signalling though they have opposing effects in activation 
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(ZEB1) and repression (ZEB2) of target genes.53  Functions include repression of tight 
junction proteins claudin-4, zona occludens protein 3, and desmosome protein 
plakophilin-2, and the activation of vimentin and matrix metalloproteinase 2 (MMP2) 
expression.54  ZEB proteins are subject to microRNA regulation by the miR-200 family 
and miR-205 adding a layer of complexity to EMT regulation.55   
The main EMT-related helix-loop-helix transcription factors are the twist-related proteins 
1 and 2 (TWIST1 and TWIST2).  Predominantly expressed in neural crest cells during 
embryogenesis, mutations in TWIST lead to defective neural tube closure at the head in 
mouse models, suggesting a role in EMT.56  TWIST expression has been observed in 
several types of malignant human tumours including melanoma, invasive lobular breast 
carcinomas and diffuse-type gastric cancers.57-59  As with the other transcription factors, 
TWIST acts to repress cell-cell adhesion genes E-cadherin, occludin, and claudin-7 while 
increasing expression of vimentin and enhancing migratory capabilities.57  TGFβ has 
been shown to induce TWIST promoter activity involving SMAD4 activity and likely 
SMAD2 and 3.60  A link between TWIST and BMP-related SMADs has yet to be 
specifically demonstrated in the literature. 
Given that the survivability of NETs drastically decreases once a metastatic event has 
occurred, an understanding of the mechanisms involved in NET progression may uncover 
novel prognostic biomarkers and therapeutic targets that can extend the overall survival 
time of this disease.  Other studies that have looked at the role of EMT markers in GEP-
NETs have shown the potential relevance of this process in the differential diagnosis of 
small versus large cell G3 tumours but have yet to demonstrate evidence of EMT in these 
tumours.61  Determining whether this early initiating step in metastasis exists in GEP-
NETs will also contribute to the limited body of knowledge surrounding the biology of 
NETs. 
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1.6 Rationale 
To gain a better understanding of the biology of gastroenteropancreatic neuroendocrine 
tumours which may lead to better diagnostic and therapeutic targets. 
 
1.7 Hypothesis 
Epithelial to mesenchymal transition is involved in the pathogenic progression of GEP-
NETs. 
 
1.8 Specific Aims 
1. To profile and identify gene expression patterns of primary and secondary GEP-
NETs indicative of an EMT event. 
2. To confirm gene expression findings at the protein level and provide evidence of 
EMT occurring in GEP-NETs. 
3. To study differences between GEP-NETs of different primary sites, clinical 
grades, and metastatic status with respect to EMT. 
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Chapter 2  
2 Materials and Methods 
2.1 Clinical Samples 
Surgically resected samples of primary neuroendocrine tumours originating from the 
small intestine (SI-NET), pancreas (P-NET), and distal colon/rectal region (R-NET), as 
well as liver metastases derived these sites were retrieved from the pathology archives at 
the London Health Sciences Centre (London, ON Canada) with approval from UWO 
Health Sciences Research Ethics Board and LHSC Pathology Archives Committee.  The 
case group was mostly limited to grade 1 (G1) and grade 2 (G2) well-differentiated GEP-
NETs, as defined by the 2010 WHO guidelines.  The majority of samples were obtained 
between 2003 and 2014.  A total of 107 unique cases were studied with 42 cases having 
both primary and secondary tumours available for study.  Table 2.1 further describes the 
cases studied. 
Table 2.1. Cases studied divided by (A) site of origin, (B) grade, and (C) metastasis 
status. 
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2.2 Tissue Microarray Construction 
Tissue microarrays (TMA) were constructed using manual tissue arrayer (Beecher 
Instruments MTA-1 Model; Sun Prairie, WI, United States).  Blank paraffin blocks were 
shaved down to a smooth, flat surface to serve as recipient blocks.  Three 0.6 mm cores 
were sampled from each case where possible depending on tissue availability and placed 
into the recipient paraffin block to make a TMA block.  A hematoxylin and eosin (H&E) 
stained slide from the donor block was used to verify and aid in targeting areas of 
tumour.  The TMA was then placed upside down onto a glass slide and placed in an oven 
at 40°C for 40 minutes.  After removing the TMA and glass slide from the oven, the slide 
was gently pressed down onto the TMA block to ensure cores were flush against the 
surface of the slide.  The glass slide was then removed to complete the TMA block.  
 
2.3 Immunohistochemistry 
TMA blocks were sectioned at 4 µm and placed on a charged glass slide for 
immunohistochemistry (IHC) work up.  The cut sections were then deparaffinized in 
xylene for several minutes and rehydrated through a graded ethanol series.  Washes were 
done using Tris-buffered saline (TBS) +/- tween 20 measured at a pH of 7.6.  Depending 
on the antibody used, a specific antigen retrieval method and dilution was used as 
outlined in Table 2.2.  The immunohistochemical signal was amplified using the avidin-
biotin complex and visualized with horseradish peroxidase.  Validation and optimization 
of each antibody was done using a separate TMA comprised of several colorectal 
cancers.  The staining in each core was semi-quantitatively evaluated based on an 
intensity score and, in certain stains, also had a percentage of cells stained score (Table 
2.3) which could be multiplied together to give an individual immunoreactivity score 
(IRS).  The staining pattern was also noted in the evaluation.  Assessment of these 
parameters was done using the Olympus BX51 microscope (Centre Valley, PA). 
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Table 2.2: Antibodies used for immunohistochemistry 
Target Host species Catalogue name 
Antigen 
retrieval 
Dilution 
SNAIL+SLUG Rabbit 
polyclonal 
AB85936 Low 1:400 
p-mTOR Rabbit 
monoclonal 
S448 (49F9) High 1:50 
p-4EBP1 Rabbit 
monoclonal 
Thr37/46 (236B4) High 1:100 
PTEN Rabbit 
monoclonal 
(D4.3) XP High 1:50 
Vimentin Mouse 
monoclonal 
Clone V9 
DAKO IR630 
High RTU 
Beta-Catenin Mouse 
monoclonal 
Clone β-Catenin-1 
DAKO IR702 
High RTU 
E-Cadherin Mouse 
monoclonal 
Clone NCH-38 
DAKO IR059 
High RTU 
p-SMAD2/3 Rabbit 
polyclonal 
SC-11769-R Low 1:200 
p-SMAD1/5/8 Rabbit 
polyclonal 
SC-12353-R Low 1:50 
SMAD4 Mouse 
monoclonal 
SC-7966 High 1:200 
Ki-67 Mouse 
monoclonal 
MIB-1 
DAKO IR626 
Low RTU 
Note: RTU stands for “ready to use”. Antigen retrieval solution pH as measured in lab: 
Low pH = 5.3 (citrate); High pH = 8.3 (Tris/EDTA). 
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Table 2.3: Immunohistochemistry scoring system 
Staining intensity Score  % of Cells stained Score 
Negative 0  1-10% 1 
Weak 1  11-50% 2 
Moderate 2  51-80% 3 
Strong 3  >80% 4 
 
2.4 RNA Extraction and Real Time RT-PCR 
For RNA extraction, two 1 mm cores were sampled from the formalin fixed, paraffin 
embedded (FFPE) tissue blocks using a biopsy punch (Integra Miltex; York, PA, USA).  
Similar to the TMA construction, an H&E slide was referred to in order to ensure the 
sampled area was tumour tissue.  RNA was extracted from the sampled cores using a 
High Pure FFPE RNA Micro kit (Roche; Laval, Quebec, Canada) and quantified with the 
Qubit Broad Range RNA assay and Qubit Fluorometer (Life Technologies; Burlington, 
Ontario, Canada).  To facilitate the RNA extraction yield, disposable tissue grinder 
pestles (Axygen PES-15-B-SI; Capitol Scientific, Austin, TX, USA) were used during the 
digestion step.  cDNA synthesis was done with an iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA, USA).  
For the pathway specific 96-well RT2 Profiler PCR Arrays (Qiagen; Mississauga, 
Ontario, Canada) (Table 2.4), cDNA was mixed with RT2 SYBR Green Mastermix 
(Qiagen).  PCR reactions were performed for 50 cycles using 25 µL per well at a 
temperature profile of 95°C for 10 minutes at initial denaturation, then cycling through 
95°C for 15 seconds and then 60°C for 1 minute as recommended by the manufacturer. 
The resulting data was normalized to five housekeeping genes (β-actin, β2 microglobulin, 
glyceraldehyde-3-phosphate dehydrogenase, hypoxanthine phosphoribosyltransferase 1, 
and large ribosomal protein P0).   
For PCR using individually purchased primers (Table 2.5), the cDNA was mixed with 
SsoFast EvaGreen Supermix (Bio-rad; Misssissauga, Ontario, Canada). These results 
were normalized to β-actin.62  In these PCR reactions, the sample volume was 20 µL 
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performed for 45 cycles with a temperature profile of 95°C for 2 minutes initially, then 
cycling through 95°C for 2 seconds and then 55°C for 12 seconds as recommended by the 
manufacturer.  
In both instances, gene expression levels of the primary and metastasis groups were 
normalized to their respective normal epithelial tissue based on site and fold change was 
determined using the 2-∆∆CT method.63 Melting curve analysis was used to assess PCR 
specificity from a temperature spectrum of 65°C – 95°C at 0.2°C increments for 5 
seconds.  
 
Table 2.4: RT2 profiler PCR arrays used 
Array Catalogue number 
Angiogenesis PAHS-024Z 
EMT PAHS-090Z 
mTOR signalling PAHS-098Z 
PI3K-AKT signalling PAHS-058Z 
 
Table 2.5: Individual primers used for PCR 
Target gene Catalogue number 
SNAI1 QT00010010 
TWIST1 QT00011956 
ZEB1 QT00020972 
ZEB2 QT00008554 
TGFB1 QT00000728 
TGFBR1 QT00083412 
BMP1 QT00000819 
BMP2 QT00012544 
BMPR1B QT00084469 
BMPR2 QT00226065 
BMPR1A QT00085358 
PTEN QT00086933 
HIF1A QT00083664 
MMP2 QT00088396 
MMP9 QT00040040 
E-CAD QT00080143 
VIM QT00095795 
ACTB QT01680476 
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2.5 Statistical Analysis 
All the statistical analyses were done using GraphPad Prism 5 (La Jolla, CA, USA). 
Statistical analysis for immunohistochemistry studies was done using an unpaired t-test 
or one-way ANOVA with Tukey’s multiple comparison post hoc test. For gene 
expression studies, analysis was conducted using the Mann-Whitney test or Kruskal-
Wallis test (with Dunn’s multiple comparison post hoc test) where appropriate.  
Correlation analyses were done using Pearson’s correlation, χ2 tests, or Fisher’s exact 
test.  For all statistical tests done, a p-value of < 0.05 was considered significant. 
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Chapter 3  
3 Results 
3.1 An EMT phenotype in GEP-NETs defined by IHC 
In pilot real time RT-PCR experiments, we focused on angiogenesis-related genes 
because GEP-NETs are well known to be highly vascular tumours.  We limited our initial 
survey to primary tumours and liver metastases originating from SI-NETs, as these are 
the most common of the GEP-NETs.  Overall, gene expression results showed elevated 
vascular endothelial growth factor (VEGF) receptor and ligand expression patterns, 
increased expression of TGFβ related genes and growth factors, and variations in 
expression patterns of ECM remodeling genes (Figure 3.1).  This pattern pointed towards 
a gene expression profile that facilitates cell guidance and migration, possibly associated 
with EMT, which led us to confirm these findings using immunohistochemistry (IHC). 
The expression of E-cadherin, β-catenin, and vimentin was studied using IHC to 
determine whether an EMT phenotype exists and how it would be defined in GEP-NETs 
from the small intestine, pancreas, and rectum.  The majority of cases showed an 
expected epithelial staining pattern of membrane staining E-cadherin and β-catenin, with 
no vimentin expression (Figure 3.2).  However, a subset of cases from each GEP-NET 
site of origin displayed a clear EMT phenotype, i.e. lack of E-cadherin and β-catenin 
membrane reactivity, with vimentin staining (Figure 3.3).  There were also cases which 
show an “in transition” phenotype where E-cadherin and β-catenin membrane staining 
was intact, as expected in an epithelial derived tumour, but also had vimentin reactivity 
(Figure 3.4).  Based on a survey of all the cases represented in the TMAs, we defined an 
EMT phenotype as loss of E-cadherin/β-catenin membrane reactivity and/or vimentin 
expression, similar to definitions used by other groups.61  Using this definition, we saw 
that a large proportion of P-NET cases and all of the R-NETs included in the study 
demonstrated an EMT phenotype (Figure 3.5).  We can further subdivide the EMT 
phenotype cases to those that have full EMT (loss of both E-cadherin/β-catenin 
membrane reactivity and vimentin expression), those that are “in transition” (E-
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cadherin/β-catenin membrane staining is intact, with vimentin reactivity), or those with 
“integrity lost” (loss of E-cadherin/β-catenin integrity only with no vimentin reactivity). 
The remaining cases that have E-cadherin/β-catenin integrity with no vimentin reactivity 
were considered to have a non-EMT phenotype.  
Of interest, there was a notable amount of variability in staining reactivity and percentage 
of cells staining among core samples from a given tumour (Figure 3.6), reinforcing the 
notion of heterogeneous EMT-associated protein expression within these tumours.  This 
raises the possibility that location of sampling within a given tumour and/or timing of the 
EMT transition affects the likelihood of capturing the transition in our sampling.  
These results show that an EMT phenotype exists among GEP-NETs, to varying degrees 
of transition, suggesting that EMT does occur in these tumours.  Furthermore, there is a 
higher prevalence of EMT among GEP-NETs originating from the pancreas and distal 
colon/rectal region which may explain why these tumours tend to be clinical more 
aggressive.  However, EMT could be occurring more frequently than observed due to 
intratumoural heterogeneity and the possibility of failing to sample an area of EMT in a 
tumour that has undergone it.  
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Figure 3.1. Relative gene expression levels of selected genes of interest from FFPE 
primary and liver metastasis samples of SI-NETs compared to normal small 
intestinal epithelium. 
(A) Expression levels of vascular endothelial growth factor receptors and ligands, 
transforming growth factor related genes, ephrins and other growth factors and receptors. 
(B) Expression levels of matrix and matrix remodelling proteins. [Primary tumours n = 9; 
Metastasis n = 4; Normal intestine n = 3]. 
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Figure 3.2. Representative case of non-EMT phenotype in SI-NETs.  
Epithelial phenotype illustrated by membrane staining for E-cadherin and β-catenin in the 
absence of vimentin staining. Insets showing higher magnification. 
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Figure 3.3. Representative case of EMT phenotype in SI-NETs.  
Loss of membrane E-cadherin and β-catenin immunoreactivity and strong vimentin 
staining reflects a possible EMT event and is seen in both primary and liver metastasis. 
Insets showing higher magnification. 
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Figure 3.4. Representative cases of primary GEP-NETs in transition between an 
epithelial and mesenchymal phenotype.  
Potential tumor cell phenotype change as illustrated by membrane staining of E-cadherin 
and β-catenin along with strong vimentin staining. Insets showing higher magnification. 
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Figure 3.5. Breakdown of cases with or without an EMT phenotype by site of origin. 
[SB = small bowel/intestine]  
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Figure 3.6. Core biopsy replicates within a given case showing variable levels of 
staining intensity and percentage of cells staining.  
Differential expression levels of vimentin within a tumour mass demonstrates its 
heterogeneity and suggests that different areas of the tumour can undergo EMT at 
different stages in a given time point.  Insets showing higher magnification.  
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3.2 EMT-associated gene expression pathways 
To determine what pathways are involved in the EMT-phenotype we observed in our 
group of GEP-NETs, we decided to perform a comprehensive overview of gene 
expression studies in a number of related pathways known to be active in GEP-NETs or 
involved in EMT.  In doing so, we were able to see differences in gene expression 
between primary and metastatic lesions as well as differences among GEP-NETs from 
different anatomical areas.  
We followed up our results with a commercial EMT specific “profiler plate” (real-time 
RT-PCR panel) and expanded our scope to encompass GEP-NETs from different 
anatomical locations to determine whether EMT related genes were similarly upregulated 
at these sites (Figure 3.7).  While all showed increased expression for certain EMT 
associated genes, the magnitude of change differed amongst the tumour groups.  P-NETs 
consistently had the greatest fold change increases for genes such as ZEB1, TGF-β1, 
TGF-β3, MMP9, fibronectin 1 (FN1) and an assortment of collagens.  Interestingly, there 
was an increase in BMP1 and BMP2 expression among SI-NETs which was not seen in 
P-NETs or R-NETs.  High tissue inhibitor of metalloproteinase 1 (TIMP1) expression in 
these tumours was apparent and to be expected as a normal neuroendocrine trait 
according to literature.64 
To round out our comprehensive overview of GEP-NETs, we included panels for genes 
associated with the mTOR and PI3K-AKT pathways (Figure 3.8 and Figure 3.9).  As 
previously mentioned in the introduction, the PI3K-AKT/mTOR pathway has been 
demonstrated to have a key role in GEP-NET tumorigenesis.  Furthermore, recent studies 
have revealed that mTOR activation, via mTORC2, is responsible for the translational 
regulation leading to changes in cell size and invasion resulting from TGF-β-signalling 
pathway activation.65, 66  Therefore, there certainly may be linkages between TGFβ and 
mTOR pathways.  In genes that overlap these two panels, such as AKT1, 2, and 3, we see 
similar patterns of expression giving us confidence in assay consistency.  Notable 
observations include the elevated expression level of hypoxia inducible factor 1 alpha 
(HIF1α) and insulin-like growth factor-binding protein 3 (IGFBP3) in the P-NETs.  
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These gene expression patterns corroborate with the EMT expression profile illustrated 
by the initial angiogenesis array.  The EMT related gene panel points towards the TGF-β 
signaling pathway with upregulation of TGF-β1 ligand and SMAD2 expression, which 
relays TGF-β into the cell.  The upregulation of ZEB1 transcription factor may be the link 
defining the effect of SMAD2 transcriptional influence and EMT action as ZEB proteins 
are known to both interact with SMAD proteins and repress genes responsible for E-
cadherin expression leading to EMT.   Elevated expression levels of HIF1α and IGFBP3, 
revealed by the mTOR pathway panels, offer other potential genes that can drive a cell 
towards EMT and regulate TGFβ-SMAD signalling respectively. Lastly, the expression 
of BMP proteins, a separate member of the TGFβ superfamily, in SI-NETs suggests that 
GEP-NETs from different sites could rely on different signalling pathways to drive their 
EMT progression.  Overall these experiments have highlighted that genes belonging to 
the TGFβ/BMP/SMAD signalling axis are actively transcribed in GEP-NETs.  
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Figure 3.7. Expression of EMT associated genes in P-NETs, SI-NETs, and R-NETs 
compared against respective site specific normal epithelium.  
[P-NET tumour n = 8, normal pancreas n = 8; SI-NET tumour n = 9, normal small 
intestine n = 9; R-NET tumour n = 8, normal colon/rectum epithelium n = 3]. 
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Figure 3.8. Expression of mTOR associated genes in P-NETs, SI-NETs, and R-NETs 
compared against respective site specific normal epithelium. 
[P-NET tumour n = 8, normal pancreas n = 8; SI-NET tumour n = 9, normal small 
intestine n = 9; R-NET tumour n = 8, normal colon/rectum epithelium n = 3]. 
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Figure 3.9. Expression of PI3K-AKT associated genes in P-NETs, SI-NETs, and R-
NETs compared against respective site specific normal epithelium. 
[P-NET tumour n = 8, normal pancreas n = 8; SI-NET tumour n = 9, normal small 
intestine n = 9; R-NET tumour n = 8, normal colon/rectum epithelium n = 3]. 
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3.3 Correlating EMT gene expression with an EMT 
phenotype 
In the next experiment, we sought to determine whether there was a relatable trend in 
gene expression with the EMT phenotype.  For example, we would expect to see that 
those cases showing an EMT phenotype at the IHC level would have higher expression of 
genes related to the mesenchymal phenotype and a decreased expression level of genes 
related to the epithelial phenotype.  Based on our primary data, we selected 17 genes 
related to EMT signalling to study on a group of 27 cases of P-NETs, some of which only 
had a primary lesion, and others with both primary and metastasis (Table 2.5).  TGF-
β/BMP receptor and ligand genes were selected to confirm our findings from the RT-
PCR panels, along with EMT transcription factors and MMPs known to be associated 
with this pathway’s activation.  EMT markers E-cadherin and vimentin were also 
included as well.  Clinical data regarding the grades, and metastatic status was correlated 
with these cases.  We focused on pancreatic NETs due to results showing a higher 
percentage of an EMT phenotype occurring in these tumours (Figure 3.5) compared to 
GEP-NETs from other sites, as well as the greater magnitude of gene expression changes 
seen in this group in RT-PCR array studies. 
Though most of these results do not reach significance when considering all unique cases 
of primary and secondary NETs, there is a trend in vimentin mRNA expression between 
EMT and non-EMT groups (Figure 3.10), with a higher expression in the EMT group 
which is to be expected in a cell transitioning towards a mesenchymal phenotype. This is 
consistent with transitioning towards a mesenchymal phenotype, and lends credibility to 
our IHC-based classification of these cases.  Significantly higher expression of bone 
morphogenetic protein receptor 2 (BMPR2), which are part of the TGFβ/BMP 
superfamily, was observed in the EMT group compared to non-EMT group (Figure 
3.11).  When looking at the EMT phenotype subsets, the only significant difference is in 
gene expression for ZEB1, an EMT transcription factor linked with TGFβ/BMP 
downstream signalling, between cases with E-cadherin/β-catenin integrity lost, and the 
“in transition” subsets (Figure 3.12).  A similar trend (not statistically significant) is seen 
with EMT transcription factor TWIST.  No remarkable differences can be seen in the 
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remaining genes studied by their EMT phenotype subsets, including other EMT 
transcription factors SNAIL and TWIST (Data not shown). 
When we exclude the metastatic NETs from the group and only consider the primary 
tumours in the group, BMPR2 appears to retain a significantly higher level of expression 
in the EMT group compared to the non-EMT group (Figure 3.14, Figure 3.13). Further 
dividing this group into the EMT phenotype subsets show no significant differences 
across the genes studied. (Data not shown).  
Importantly, we also correlated gene expression differences based on clinical features, 
including tumour grade, presence or absence of metastasis, and type of metastasis (lymph 
node versus liver).  With respect to grade, vimentin is significantly more highly 
expressed in G2 tumours, while BMPRIβ and MMP9 are more highly expressed in G1 
tumours (Figure 3.15, Figure 3.16).  E-cadherin expression is significantly elevated 
among cases with no known metastasis compared to those with some metastasis (Figure 
3.17).  No other differences were observed (Figure 3.18).  When we further explore the 
type of metastasis into groupings of no metastasis, lymph node only metastasis, and liver 
metastasis (with or without lymph node involvement), the only difference in gene 
expression is seen in MMP2 where there is a higher expression in the no metastasis group 
compared to the liver metastasis group (Figure 3.19, Figure 3.20).  
Although there were few differences in gene expression between EMT and non-EMT 
group, these experiments revealed several interesting findings. The significantly higher 
expression of EMT transcription factor ZEB1 among cases “in transition” compared to 
“integrity lost only”, as well as similar trends in TWIST, suggests that gene 
transcriptional changes are more important prior to the full phenotypic onset of EMT, and 
that after EMT is achieved, their elevated expression is no longer necessary.  The 
significantly elevated gene expression levels of vimentin, an intermediate filament 
typically expressed by mesenchymal cells, may indicate that as these tumours acquire 
more mesenchymal traits, they become more clinically aggressive.  Finally, having robust 
E-cadherin gene expression seems to be a positive sign for tumours that have yet to 
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metastasize, possibly because the cell-cell contacts mediated by E-cadherin remain 
present in the tumour.   
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Figure 3.10. Expression of EMT related genes in P-NETs based on their EMT 
phenotype defined by IHC.  
Graphs show median with error bars representing interquartile range.  
[“non-EMT” n = 8; “EMT” n = 17]. 
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Figure 3.11. Expression of TGFβ/BMP signalling genes and select MMPs in P-NETs 
based on their EMT phenotype defined by IHC.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“non-EMT” n = 8; “EMT” n = 17]. 
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Figure 3.12. Expression of ZEB1 in P-NETs based on their EMT phenotype subset 
defined by IHC.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“non-EMT” n = 8; “Integrity lost only” n = 5; 
“In transition” n = 6; “EMT” n = 6]. 
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Figure 3.13. Expression of EMT related genes in primary P-NETs based on their 
EMT phenotype defined by IHC.  
Graphs show median with error bars representing interquartile range. [“non-EMT” n = 6; 
“EMT” n = 15]. 
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Figure 3.14. Expression of TGFβ/BMP signalling genes and select MMPs in primary 
P-NETs based on their EMT phenotype defined by IHC.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“non-EMT” n = 6; “EMT” n = 15]. 
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Figure 3.15. Expression of EMT related genes in primary P-NETs based on grade.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“G1” n = 10; “G2” n = 11]. 
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Figure 3.16. Expression of TGFβ/BMP signalling genes and select MMPs in primary 
P-NETs based on grade.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“G1” n = 10; “G2” n = 11]. 
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Figure 3.17. Expression of EMT related genes in primary P-NETs based on presence 
or absence of metastasis.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“Metastasis” n = 14; “No metastasis” n = 8]. 
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Figure 3.18. Expression of TGFβ/BMP signalling genes and select MMPs in primary 
P-NETs based on presence or absence of metastasis.  
Graphs show median with error bars representing interquartile range. [“Metastasis” n = 
14; “No metastasis” n = 8]. 
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Figure 3.19. Expression of EMT related genes in primary P-NETs based on their 
metastatic subsets.  
Graphs show median with error bars representing interquartile range. [“Liver metastasis” 
n = 9; “Lymph node metastasis only” n = 4; “No metastasis” n = 8]. 
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Figure 3.20. Expression of TGFβ/BMP signalling genes and select MMPs in primary 
P-NETs based on their metastatic subset.  
Graphs show median with error bars representing interquartile range. Asterisk (*) 
represents significance level of p < 0.05. [“Liver metastasis” n = 9; “Lymph node 
metastasis only” n = 4; “No metastasis” n = 8]. 
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3.4 SNAIL/SLUG protein expression among GEP-NETs 
To support the involvement of EMT in GEP-NETs, we investigated to see whether well-
established EMT transcription factors were detectable via IHC in the tumours represented 
in the TMAs.  We also wanted to determine whether there was a relationship between 
EMT transcription factor expression with the EMT phenotype previously established or 
the clinical information retained. We set out to study the immunohistochemical profile of 
SNAIL/SLUG, TWIST, ZEB1 and ZEB2, but we were only able to validate and optimize 
the SNAIL/SLUG antibody for this study on the TMAs. 
We considered the cytoplasmic and nuclear staining of this transcription factor separately 
when assigning IRS (Figure 3.21).  There appears to be no correlation between 
cytoplasmic IRS and nuclear IRS (Figure 3.22).  No significant differences were 
apparent for cytoplasmic SNAIL/SLUG staining among the different metastasis 
grouping, and different EMT phenotype groupings (Figure 3.23).  However, there was a 
significantly higher expression of the transcription factor among primary and secondary 
rectal NETs when compared to their pancreatic and small bowel counterparts (Figure 
3.24).  
On the nuclear staining side, there was a significantly higher nuclear expression of 
SNAIL/SLUG in the non-EMT grouping within secondary NETs only (Figure 3.25).  No 
significant differences are apparent when considering tumour type, site or grade (Figure 
3.26). 
In observing the immunohistochemical staining of a transcription factor, the nuclear 
staining is far more compelling than cytoplasmic presence given that the nucleus is where 
these proteins can influence further transcription. However, since there was no 
correlation between staining observed in the cytoplasm versus the nucleus, the possibility 
of different gene expression correlations existed. Indeed, it seems that R-NETs had the 
strongest cytoplasmic reactivity among the other GEP-NETs, but did not differ in nuclear 
staining.  This site-specific difference may be a reflection of how different environments 
are from one another and how the external influences from each given site could 
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influence the expression and localization of transcription factor proteins such as SNAIL 
and SLUG. 
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Figure 3.21. Representative images of TMA cores showing nuclear and cytoplasmic 
SNAIL/SLUG reactivity. 
Cases showing strong nuclear but weak cytoplasmic staining (A), compared to those with 
moderate cytoplasmic staining with no nuclear involvement (B). Overall, R-NETs (E) 
showed strong reactivity to SNAIL/SLUG compared to SI-NETs (C) and P-NET (D). 
Insets showing higher magnification.  
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Figure 3.22. Scatterplot of SNAIL/SLUG nuclear expression versus cytosolic 
expression in primary and secondary NETs.  
Pearson’s correlation coefficient, r, for “All GEP-NETs”, “Primary NETs” and 
“Secondary NETs” are -0.0479 [p = 0.5568, not significant, n = 149], -0.0564 [p = 
0.6167, not significant, n= 76], -0.0066 [p = 0.964, not significant, n = 73] respectively.  
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Figure 3.23. Cytoplasmic SNAIL/SLUG reactivity by metastasis status, and EMT 
phenotype. 
Graphs show mean with error bars representing SEM.  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.24. Cytoplasmic SNAIL/SLUG reactivity by overall tumour type, site, and 
grade. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05. n = 76 for primary NETs; n = 73 for secondary NETs.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Secondary NET “G1” n = 50, “G2” n = 18] 
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Figure 3.25. Nuclear SNAIL/SLUG reactivity by metastasis status, and EMT 
phenotype.  
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.26. Nuclear SNAIL/SLUG reactivity by overall tumour type, site, and 
grade.  
Graphs show mean with error bars representing SEM.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Secondary NET “G1” n = 50, “G2” n = 18] 
 
  
68 
 
3.5 SMAD immunohistochemistry profile in GEP-NETs 
SMAD proteins are the link between the various signalling pathways associated with 
EMT and the upregulation in the expression of EMT transcription factors.  Their presence 
in an active phosphorylated state and/or nuclear localization can indicate the activity of 
certain pathways initiating EMT.  We looked at the immunoreactivity of several SMAD 
proteins to determine whether different SMADs, and thereby different signalling 
pathways, are active among different EMT phenotypes, site of origin, grade, and 
metastatic state.  Specifically, p-SMAD2/3 is the phosphorylated product of TGFβ 
receptor activity, p-SMAD1/5/8 results from BMP signalling, and SMAD4 is the 
common SMAD that complexes with either of the other SMADs before translocating into 
the nucleus.  
Phosphorylated SMAD2/3 (p-SMAD2/3) was exclusively reactive in the nucleus with 
very weak to completely negative reactivity in the cytoplasm uniformly across the cells 
represented in the TMA cores.  Nuclear expression of p-SMAD2/3 is higher among cases 
with no metastasis (Figure 3.27).  Although nuclear reactivity does not appear to differ 
between primary and secondary NETs, primary P-NETs have a significantly higher 
nuclear immunoreactivity score for p-SMAD2/3 compared to SI-NETs (Figure 3.28).   
In p-SMAD1/5/8, both nuclear and cytosolic staining was seen among tumour cells and 
both staining patterns were evaluated.  Correlating nuclear IRS with cytosolic IRS 
revealed a weakly positive relationship among all the GEP-NETs represented and a 
moderately positive relationship exists in the secondary NETs according to their 
Pearson’s correlation coefficient (Figure 3.29).  No differences in nuclear or cytosolic 
reactivity are apparent between metastasis and EMT phenotype groupings (Figure 3.30, 
Figure 3.32), although primary P-NETs appear to be more nuclear and cytosolically 
reactive than SI-NETs (Figure 3.31, Figure 3.33).  Secondary NETs from other sites 
outside of the gastrointestinal tract appear to have higher cytosolic reactivity compared to 
P-NETs and SI-NETs (Figure 3.33).  
SMAD4 nuclear and cytosolic staining also was seen among tumour cells.  Correlating 
nuclear IRS with cytosolic IRS for this stain showed a very strong positive relationship 
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among all GEP-NETs even when separating primary and secondary NETs (Figure 3.34). 
SMAD4 nuclear reactivity is higher in cases with no metastasis compared to those with 
metastases, liver in particular (Figure 3.35).  Cases with an EMT phenotype also have 
higher nuclear reactivity compared to non-EMT cases, particularly between cases “in 
transition” (Figure 3.35).  Overall, the primary NETs are more nuclear reactive than 
secondary NETs.  However, both show many significant differences in nuclear reactivity 
among the various sites of origins and grades (Figure 3.36).  P-NETs and R-NETs have 
more SMAD4 nuclear reactivity than SI-NETs and miscellaneous NETs.  G2 tumours are 
significantly more nuclear reactive than G1 tumours.  The cytosolic reactivity follows a 
similar profile to their nuclear counterpart.  Cases with no metastasis scored significantly 
higher IRS compared to those with metastases while no differences can be seen within 
EMT phenotype groupings (Figure 3.37).  While the overall scores between primary and 
secondary NETs differ significantly, both demonstrate significantly higher IRS in P-
NETs compared to SI-NETs, and G2 tumours compared to G1 tumours (Figure 3.38).  P-
NETs had higher SMAD reactivity across all the SMAD proteins investigated which may 
relate to the higher reactivity these tumours had for SNAIL/SLUG and greater fold 
change differences seen in ZEB1 and 2 compared to the other sites (Figure 3.39).  
The SMAD protein expression patterns show that the SMAD proteins surveyed are  
localized in the nucleus, providing a readout for active signalling via TGFβ and BMP 
receptors which will presumably influence gene transcription.  SMAD4 immunoreactivity 
appears to be higher in cases with an EMT phenotype and that have more clinically 
aggressive characteristics such as grade and site (pancreas and rectal).  Although this 
does not appear to be reflected with respect to metastatic presence, as p-SMAD2/3 and 
SMAD4 proteins appear to be significantly elevated among cases that have no metastasis, 
it is possible that these tumours have yet had a chance to metastasize.   
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Figure 3.27. Phospho-SMAD2/3 nuclear reactivity by metastasis status, and EMT 
phenotype. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
 
71 
 
Primary vs secondary NETs
Pr
im
ar
y
Se
co
nd
ar
y
0
2
4
6
8
10
12
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Primary NETs by site
O
th
er
P
an
c
R
ec
t
S
B
0
2
4
6
8
10
12
*
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Secondary NETs by site
O
th
er
P
an
c
R
ec
t
S
B
0
2
4
6
8
10
12
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Primary NETs by grade
G
1
G
2
0
2
4
6
8
10
12
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Secondary NETs by grade
G
1
G
2
0
2
4
6
8
10
12
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
 
  
72 
 
Figure 3.28. Phospho-SMAD2/3 nuclear reactivity by overall tumour type, site, and 
grade. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Secondary NET “G1” n = 50, “G2” n = 18] 
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Figure 3.29. Scatterplot of p-SMAD1/5/8 nuclear versus cytosolic expression in 
primary and secondary NETs. 
Pearson’s correlation coefficient, r, for “All GEP-NETs”, “Primary NETs” and 
“Secondary NETS” are 0.2661 [p = 0.0009, significant, n = 153], 0.1816 [p = 0.1091, not 
significant, n = 79], and 0.3325 [p = 0.0038, significant, n = 74] respectively.  
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Figure 3.30. Phospho-SMAD1/5/8 nuclear reactivity by metastasis status, EMT 
phenotype and EMT phenotype subsets. 
Graphs show mean with error bars representing SEM. 
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
 [Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.31. Phospho-SMAD1/5/8 nuclear reactivity by overall tumour type, site, 
and grade. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
Graphs show mean with error bars representing SEM.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Secondary NET “G1” n = 50, “G2” n = 18] 
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Figure 3.32. Phospho-SMAD1/5/8 cytosolic reactivity by metastasis status, EMT 
phenotype and EMT phenotype subsets. 
Graphs show mean with error bars representing SEM. 
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.33. Phospho-SMAD1/5/8 cytosolic reactivity by overall tumour type, site, 
and grade. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Secondary NET “G1” n = 50, “G2” n = 18] 
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Figure 3.34. Scatterplot of SMAD4 nuclear versus cytosolic expression in primary 
and secondary NETs. 
Pearson’s correlation coefficient, r, for “All GEP-NETs”, “Primary NETs” and 
“Secondary NETS” are 0.07353 [p < 0.0001, significant, n = 153], 0.7198 [p < 0.0001, 
significant, n = 79], and 0.7195 [p < 0.0001, significant, n = 74] respectively.  
  
81 
 
 
Primary NETs by metastasis presence
M
et
as
ta
si
s
N
o 
m
et
as
ta
si
s
0
2
4
6
8
10
12 *
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Primary NETs by metastasis status
Li
ve
r
Ly
m
ph
 n
od
e 
on
ly
N
o 
M
et
as
ta
si
s
0
2
4
6
8
10
12 *
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Primary NETs by EMT phenotype
no
n-
E
M
T
E
M
T
0
2
4
6
8
10
12
*
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Secondary NETs by EMT phenotype
no
n-
E
M
T
E
M
T
0
2
4
6
8
10
12
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Primary NETs by EMT phenotype subset
no
n-
E
M
T
In
te
gr
ity
 lo
st
In
 tr
an
si
tio
n
E
M
T
0
2
4
6
8
10
12
*
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
Secondary NETs by EMT phenotype subset
no
n-
E
M
T
In
te
gr
ity
 lo
st
In
 tr
an
si
tio
n
E
M
T
0
2
4
6
8
10
12
Im
m
u
n
o
re
a
c
ti
v
it
y
 s
c
o
re
 
  
82 
 
Figure 3.35. SMAD4 nuclear reactivity by metastasis status, EMT phenotype and 
EMT phenotype subsets. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Primary NET “non-EMT” n = 37, “Integrity lost” n = 12, “In transition” n = 17, “EMT” 
n = 10]  
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
[Secondary NET “non-EMT” n = 39, “Integrity lost” n = 12, “In transition” n = 12, 
“EMT” n = 10] 
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Figure 3.36. SMAD4 nuclear reactivity by overall tumour type, site, and grade. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Secondary NET “G1” n = 50, “G2” n = 18] 
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Figure 3.37. SMAD4 cytosolic reactivity by metastasis status, EMT phenotype and 
EMT phenotype subsets. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.38. SMAD4 cytosolic reactivity by overall tumour type, site, and grade. 
Graphs show mean with error bars representing SEM. Asterisk (*) represents significance 
level of p < 0.05.  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9] 
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Primary NET “non-EMT” n = 37, “Integrity lost” n = 12, “In transition” n = 17, “EMT” 
n = 10]  
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
[Secondary NET “non-EMT” n = 39, “Integrity lost” n = 12, “In transition” n = 12, 
“EMT” n = 10] 
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Figure 3.39. Overview summary of different select stains and gene expression 
among GEP-NETs from different sites. 
Immunoreactivity scores for TGFβ/BMP downstream effectors SMADs (A) and their 
associated targets of transcription SNAIL/SLUG (C) across different GEP-NETs. 
Nuclear IRS scores shown. Gene expression data for ZEB proteins which are also 
induced by TGFβ signalling across various sites shown (B). SNAIL/SLUG and ZEB 
proteins act to repress genes expressing E-cadherin (D). Graphs showing mean ± SEM. 
Data summarized from previous figures. 
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3.6 EMT phenotype and mTOR signalling in GEP-NETs 
The mTOR pathway and its pathogenic involvement in GEP-NETs have become more 
prominent as research uncovers its contribution, especially since genes along the mTOR 
signalling axis were shown to be frequently mutated among P-NETs.20  Clinical trials 
demonstrating prolonged progression-free survival in advanced P-NETs for patients on 
mTOR inhibitor, Everolimus, prompted USA Food and Drug Administration, and Health 
Canada approval.67  Since then, the relative success with the use of mTOR inhibitors for 
patients with advanced P-NETs who have exhausted other therapeutic options provides 
evidence that this pathway is likely to have a role in GEP-NET pathogenesis.  68  Recent 
studies linking mTOR to TGFβ induced EMT,66 prompted us to study whether there may 
be a correlation with an EMT phenotype and the activation of the mTOR pathway 
through immunohistochemistry on our TMA sets.  As with our other experiments, we 
also looked at whether tumour site, grade, and metastatic status corresponded with mTOR 
pathway activation.  
We looked at three mTOR related genes:  phosphorylated mammalian target of 
rampamycin (p-mTOR), phosphorylated eukaryotic translation initiation factor 4E-
binding protein 1 (p-4EBP1), and phosphatase and tensin homolog (PTEN) (Figure 
3.40).  Phosphorylated mTOR reactivity is significantly higher in non-EMT groups than 
EMT groups in both overall and subset phenotypes within primary NETs but not 
secondary NETs (Figure 3.41).  It also appears that p-mTOR is more reactive in primary 
small bowel NETs than rectal NETs, and that G1 primary NETs are more p-mTOR 
reactive than G2 NETs (Figure 3.42).  No significant differences are apparent in p-
4EBP1 staining reactivity among all parameters checked (Figure 3.43, Figure 3.44).  
PTEN immunoreactivity appears to be significantly higher in the “no metastasis” 
grouping than the “liver metastasis” group, and in no other group parameter (Figure 3.45, 
Figure 3.46). 
To assess possible correlations, we conservatively set cases with an IRS score of 3 or 
above as staining positive, while those with an IRS score of 2 and below were negative.  
This would ensure that cases which were organized into “mTOR pathway activated” 
(cases with either p-mTOR or p-4EBP1 staining positive) had robust staining versus 
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cases sorted into “mTOR pathway inactive” (p-mTOR and p-4EBP1 negative) categories.  
No correlations were apparent based on a simple chi-squared and Fisher’s exact test 
except in primary tumours where there is an association with PTEN staining (Figure 
3.47, Figure 3.48).  
This experiment shows that the mTOR pathway appears to be more active among GEP-
NETs that are less clinically aggressive, given that G1 tumours, non-EMT NETs and SI-
NETs had higher immunoreactivity to p-mTOR.  Possibly of greater importance, it 
appears that PTEN is significantly more reactive among cases that have no metastasis, 
suggesting that PTEN may play a key role in suppression of aggressive behaviour.  These 
two observations together suggest that mTOR signaling is active in GEP-NETs, and that 
disease progression could occur when there is mTOR dysregulation at the PTEN level.    
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Figure 3.40. Immunoreactivity scores of mTOR pathway related stains.  
Graphs showing mean with SEM. Asterisk (*) represents significance level of p < 0.05. . 
[n = 76 for primary NETs and n = 73 for secondary NETs for each stain]. 
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Figure 3.41. Immunoreactivity score of p-mTOR based on EMT phenotype and 
subsets.  
Graphs showing mean with SEM. Asterisk (*) represents significance level of p < 0.05. 
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Primary NET “non-EMT” n = 37, “Integrity lost” n = 12, “In transition” n = 17, “EMT” 
n = 10]  
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
[Secondary NET “non-EMT” n = 39, “Integrity lost” n = 12, “In transition” n = 12, 
“EMT” n = 10] 
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Figure 3.42. Immunoreactivity score of p-mTOR based on site of origin, grade, and 
metastasis status.  
Graphs showing mean with SEM. Asterisk (*) represents significance level of p < 0.05. 
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]  
[Secondary NET “G1” n = 50, “G2” n = 18]  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9]  
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
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Figure 3.43. Immunoreactivity score for p-4EBP1 based on EMT phenotype.  
Graphs showing mean with SEM.  
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.44. Immunoreactivity score of p-4EBP1 based on site of origin, grade, and 
metastasis status.  
Graphs showing mean with SEM.  
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]  
[Secondary NET “G1” n = 50, “G2” n = 18]  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9]  
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
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Figure 3.45. Immunoreactivity score for PTEN based on EMT phenotype.  
Graphs showing mean with SEM.  
[Primary NET “non EMT” n = 37, “EMT” n = 39]   
[Secondary NET “non-EMT” n = 39, “EMT” n = 33]  
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Figure 3.46. Immunoreactivity score of PTEN based on site of origin, grade, and 
metastasis status.  
Graphs showing mean with SEM. Asterisk (*) represents significance level of p < 0.05. 
[Primary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]   
[Primary NET “G1” n = 51, “G2” n = 21]  
[Secondary NET “Other” n = 2, “Panc” n = 26, “Rect” n = 3, “SB” n = 45]  
[Secondary NET “G1” n = 50, “G2” n = 18]  
[Primary NET “Metastasis” n = 67, “No metastasis” n = 9]  
[Primary NET “Liver” n = 55, “Lymph node only” n = 12; “No metastasis” n = 9] 
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Figure 3.47. Contingency graphs for mTOR pathway activity in EMT phenotypes 
and metastasis status. 
Chi-squared and Fisher’s exact test show no significant correlations. 
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Figure 3.48. Contingency graphs for mTOR pathway activity in PTEN status, site of 
origin, and grade. 
Chi-squared and Fisher’s exact tests show no significant correlations except in primary 
tumours where there is an association with PTEN status. 
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Chapter 4  
4 Conclusions 
4.1 Discussion 
Although EMT has been demonstrated in vitro for other epithelial tumours, this study is 
the first to show that EMT is involved in the pathogenic progression of GEP-NETs.  We 
established the presence of an EMT phenotype using epithelial and mesenchymal 
markers and in doing so, discovered interesting expression patterns and trends among the 
cases represented in our group of GEP-NETs.  Although alterations of E-cadherin and β-
catenin have been noted in GEP-NETs within literature,61, 69 this is the first to show 
concomitant expression of mesenchymal marker, vimentin.  Previous studies have 
attempted, but failed to demonstrate vimentin expression within GEP-NETs outside of 
the stromal cells.70  Vimentin is a well-known intermediate filament present in 
mesenchymal cells that aids in anchoring organelles within the cytoplasm during any sort 
of mechanical stress, be it external or for self-propulsion.  Among the cases with E-
cadherin/β-catenin loss of integrity and membrane staining, the majority of this group 
showed β-catenin sequestered in the cytoplasm.  β-catenin is typically expected to either 
translocate into the nucleus to act as a transcription factor, or be subjected to ubiquitin-
mediated protein degradation when it loses its association with E-cadherin.71  The 
presence of β-catenin remaining in the cytoplasm suggests that another signalling 
pathway, Wnt, may be active in stabilizing the protein.40  Wnt signalling is a pathway 
commonly associated with EMT and the preservation of a stem cell phenotype.72  
The high proportion of P-NETs and all of the R-NETs displaying an EMT phenotype 
comparted to SI-NETs is interesting, given that NETs from these sites tend to behave 
more aggressively.73-75  Knowing this, it is possible that part of their aggression comes 
from a tendency towards an EMT occurrence allowing for greater opportunity for 
metastasis which is ultimately what patients succumb to.  
Heterogeneity of these tumours was apparent in our IHC staining analyses.  A number of 
cases showed markedly different staining patterns and intensity across core replicates 
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from the same tumour using various immunohistochemical stains used in the study.  This 
is not necessarily surprising, as EMT is likely not occurring simultaneously across all 
tumour cells at a given time.  In fact, it seems more likely that a few single or clustered 
cells may transition to an EMT phenotype at a certain point in time.70  The location of 
these cells may influence the likelihood of EMT.  For instance, EMT could be more 
frequent in cells at the leading edge of a tumour or in cells immediately adjacent to blood 
vessels that would facilitate its eventual dissemination and metastasis.  Indeed, studies 
have shown differential expression levels of key genes such as β-catenin within tumours 
where the cells from leading edges have elevated mRNA expression compared to those 
from the inner parts.76  The heterogeneity of staining that we have observed may also 
mean that some cases with no evidence of an EMT immunophenotype may be 
misrepresented due to sampling artifact.  Interestingly, staining differences were apparent 
among cases with paired primary and secondary lesions as well, although this might be 
expected as research reveals that despite sharing similar origins, primary tumour and their 
metastases may not share the same characteristics.77, 78  Despite all of this, validation 
studies employing the use of TMAs on FFPE breast and ovarian cancer specimens have 
shown that a single 0.6 mm core is sufficient to represent a tumour for protein expression 
studies, with increasing accuracy with greater replicates.79, 80  Emphasis was placed in 
sampling different areas, especially from areas of the edges and core were essential when 
taking replicate cores for an immunohistochemical profile.81 
TGFβ has been shown to reduce E-cadherin expression as a result of upregulating 
promoter activity on EMT transcription factors SNAIL/SLUG via downstream effector 
SMAD complexes.47, 49  Our SNAIL/SLUG and SMAD series of immunohistochemical 
stains help highlight the significance of identifying nuclear staining as these proteins are 
relevant for their ability to regulate cellular transcription.  The immunohistochemistry 
shows us that not only are EMT transcription factors and downstream signalling 
molecules present in the GEP-NETs, but they are also localized to the nucleus where they 
actively influence transcription.  Although few differences were seen among the 
SNAIL/SLUG staining, the SMAD proteins investigated seem to suggest that SMAD 
activity is particularly active among P-NETs relative to SI-NETs overall.  Cases that had 
not metastasized had higher p-SMAD2/3 and SMAD4 reactivity than those with 
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metastases, but with no difference in p-SMAD1/5/8 reactivity, seem to suggest a more 
active role of TGFβ signalling over BMP signalling among primary NETs.  SMAD4 
reactivity patterns fall in line with its tumour suppressor properties as it has been shown 
the absence of it is seen in higher frequency among colorectal cancers with distant 
metastases, and later associated with worse overall survival.82, 83  The immunoreactivity 
patterns observed in these stains suggest that TGFβ signalling is needed early in the EMT 
process but after EMT and metastasis are achieved, its dysregulation may be more 
advantageous.  
One of the caveats to our gene expression studies is the quality of starting genetic 
material used.  Although we extracted our RNA from FFPE tissue, we are satisfied by the 
quality and consistency of the results yielded in our gene expression studies.  Other 
studies have also demonstrated the feasibility and potential to use DNA and RNA 
extracted from FFPE specimens with success.84  Certain features, such as the high 
expression of TIMP1, which has been cited in literature as a normal neuroendocrine cell 
expression tendency, help reassure the reliability of our results.64  The consistency in 
relative expression among overlapping genes represented across the various profiler 
plates such as the VEGF ligands, AKT1/2/3, and TSC1 further supports this.  Ultimately, 
we treated our profiler plate gene expression studies as a way to obtain a general 
overview of what is happening in the collective of GEP-NETs in order to aid in selecting 
specific genes and signalling pathways to focus future studies on.  
The individual case based PCR reaction experiments helped show that cases with an 
EMT phenotype at the protein level also have elevated vimentin mRNA expression, at 
least among all samples of GEP-NETs.  The lack of changes seen in EMT versus non-
EMT groups specifically may be a reflection on the focal nature of the EMT phenotype 
seen in many cases.  Additionally, changes in subcellular localization of key EMT-related 
proteins, like E-cadherin or β-catenin, may not necessarily be reflected at the mRNA 
level as decreased expression. Going forward, adding additional cases to our series may 
help some of the results reach statistical significance.  However, certain significant 
differences were discovered.  Elevated expression of BMPRIα and BMPR2 in the overall 
EMT group suggest the involvement of the BMP branch of the TGFβ superfamily.  The 
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expression of ZEB1 being significantly higher in cases “in transition” versus those with 
“integrity lost” only suggests that the expression of these transcription factors precedes 
the full onset of EMT and taper off after the transition begins.  The potential clinical 
correlation of vimentin being more highly expressed in G2 tumours versus G1 suggest 
vimentin could be a biomarker for aggressive tumour behaviour.  E-cadherin was seen to 
be more highly expressed in cases with no known metastases verses those that had some 
which further highlights the importance of retaining cell-cell contacts when maintaining 
an epithelial phenotype.  This fits with the EMT process as the loss of E-cadherin is a key 
hallmark of the transition and the suppression of intercellular interactions mediated by E-
cadherin may be a separate trigger of EMT on its own.  Elevated MMP expression levels 
seen in G1 tumours for MMP9 and tumours without metastases for MMP2 could provide 
the means of initiating EMT as these MMPs can cleave latent TGFβ ligands sequestered 
in the ECM.30  
Our mTOR pathway related immunohistochemistry suggests that mTOR signalling plays 
a larger role among non-EMT cases, small bowel NETs and G1 tumours overall, 
characteristics commonly associated with less aggressive clinical behaviour.  This 
activation may be strictly regulated with higher PTEN expression since cases that remain 
non-aggressive as primary NETs with no metastasis had elevated PTEN expression.  This 
upstream control seems to be reduced in cases with known liver metastasis.  Indeed, 
PTEN loss has been associated with poorer outcomes and higher grade in prostate 
cancer85, 86  Early PTEN dysregulation may be an early step in overall elevated mTOR 
activity in cases that have yet to show aggressiveness.  Lack of correlation between p-
4EBP1 expression with any of our clinical parameters appears to agree with similar 
studies done immunohistochemically profiling mTOR pathway proteins in P-NETs.87  
The mTOR pathway seems to be more active in cases that retain their epithelial 
phenotype, have yet to metastasize, or overall appear to be clinically less aggressive 
which seems counter-intuitive to the cases of advanced P-NETs that have benefitted from 
mTOR inhibitor therapies. 
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4.2 Future Directions 
Overall, this study demonstrates there is EMT associated with GEP-NETs. It is difficult 
to definitively say which of the many potential pathways are inducing this process. 
However given our observations, TGFβ/BMP signalling pathway and EMT transcription 
factors associated with its activation are present and could be related to the EMT 
described.  Certain elements in the EMT process may be useful as biomarkers indicating 
aggressive clinical behaviour such as loss of membrane E-cadherin or gain of vimentin 
expression.  Molecularly, to further appreciate the role of EMT in GEP-NETs, a living 
model system needs to be used.  Currently, several human cell lines exist for the disease, 
including the CNDT288, GOT-189, and KRJ-I cell lines90, as well as the STS91 cell line 
series.  However, the utility of each have their own problems when replicating the 
neuroendocrine phenotype which has cast doubt on their appropriateness in replicating 
disease.  A cell model is needed to test whether cells respond to certain ligands of 
specific signalling systems to see if they recapitulate an EMT event.  
The notably high gene expressions of HIF1α and IGFBP3 from the real-time RT-PCR 
panels remains to be investigated in future studies as well.  It is known that HIF1α is a 
transcription factor upregulated in the hypoxic environment frequently found in 
cancers.92  Similarly, IGFBP3 expression has been noted in hypoxic tumour 
environments of esophageal cancer and shown to contribute to tumour progression with 
growth stimulation.93  Additional studies have shown that IGFBP3 is a hypoxia-inducible 
gene and that HIF1α is capable of inducing its mRNA expression.94  This environment 
enhancing IGFBP3 has been found to facilitate TGFβ1-mediated EMT, independent of its 
IGF-binding capacity, by stabilizing SMAD2/3 phosphorylation.95  This gives motivation 
that given the expression patterns seen in HIF1α and IGFBP3, it is possible that they 
contribute towards EMT by allowing persistent phosphorylation of SMAD2/3, 
subsequently upregulating EMT transcription factors.  Investigating these leads may 
expand on the interplay between mTOR and TGFβ/BMP signalling in these tumours. 
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